Severe Preeclampsia During Pregnancy Linked With Late-Life Cognitive Issues, Inflammation
August 4th 2022Inflammatory coagulation pathway activator positive extracellular vesicles were significantly increased in women with a history of severe preeclampsia compared with controls and those with milder cases.
Technological Advancements Improving, Expanding Capabilities of Antibody Testing: Sean Pittock, MD
July 17th 2022The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the technological capabilities the center has, including the improved use of neural antibody testing. [WATCH TIME: 6 minutes]
Distinguishing and Diagnosing Various Presentations of Autoimmune Encephalitis: Sean Pittock, MD
July 5th 2022The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the complexities in diagnosing autoimmune encephalitis and the approach needed to be taken. [WATCH TIME: 5 minutes]
The Aducanumab Saga and the Future of Antiamyloid Monoclonal Antibodies
June 13th 2022The journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.
Aberrant Sleep Patterns Show Risk Associated With Status Migrainosus Recurrence
June 11th 2022Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.
Eculizumab Shows Better Prolonging of Time to NMOSD Relapse Than Other Treatments
October 17th 2021An indirect comparison study evaluated relative treatment effects of eculizumab (Soliris; Alexion), inebilizumab (Uplizna; Horizon), and satralizumab (Enspryng; Genentech), the 3 FDA-approved options for NMOSD.
Cutting Edge Care in Multiple Sclerosis: Advances in S1P Therapy
July 28th 2021Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).